Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation

12Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Chagas and COVID-19 are diseases caused by Trypanosoma cruzi and SARS-CoV-2, respectively. These diseases present very different etiological agents despite showing similarities such as susceptibility/risk factors, pathogen-associated molecular patterns (PAMPs), recognition of glycosaminoglycans, inflammation, vascular leakage hypercoagulability, microthrombosis, and endotheliopathy; all of which suggest, in part, treatments with similar principles. Here, both diseases are compared, focusing mainly on the characteristics related to dysregulated immunothrombosis. Given the in-depth investigation of molecules and mechanisms related to microthrombosis in COVID-19, it is necessary to reconsider a prompt treatment of Chagas disease with oral anticoagulants.

Cite

CITATION STYLE

APA

Pérez-Campos Mayoral, L., Hernández-Huerta, M. T., Papy-García, D., Barritault, D., Zenteno, E., Sánchez Navarro, L. M., … Pérez-Campos, E. (2021). Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation. Molecular and Cellular Biochemistry, 476(10), 3815–3825. https://doi.org/10.1007/s11010-021-04204-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free